Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | CXCR6 | O00574 | 3/20 | 0.49 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.49 |
| ▸ | MMP2 | P08253 | 2/20 | 0.47 |
| ▸ | ANPEP | P15144 | 2/20 | 0.47 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21861008 | 0.88 | MAPK1 (0.50) | MAPK1OPRK1TSHRCXCR6CXCR4 | |
| SCHEMBL24245441 | 0.86 | MAPK1 (0.48) | MAPK1OPRK1TSHRCXCR6CXCR4 | |
| SCHEMBL21860504 | 0.85 | MAPK1 (0.52) | MAPK1OPRK1TSHRCXCR6CXCR4 | |
| SCHEMBL21928911 | 0.84 | MAPK1 (0.58) | MAPK1OPRK1TSHRMMP2ANPEP | |
| SCHEMBL21834930 | 0.84 | MAPK1 (0.58) | MAPK1OPRK1TSHRCXCR6CXCR4 | |
| SCHEMBL21860515 | 0.84 | MAPK1 (0.47) | MAPK1OPRK1TSHRCXCR6MMP2 | |
| SCHEMBL21926859 | 0.80 | CXCR6 (0.58) | MAPK1OPRK1CXCR6CXCR4 | |
| SCHEMBL21927008 | 0.80 | ALDH1A1 (0.61) | MAPK1OPRK1TSHRCXCR6MMP2 | |
| SCHEMBL21860513 | 0.79 | MAPK1 (0.46) | MAPK1OPRK1TSHRCXCR6CXCR4 | |
| SCHEMBL10123862 | 0.79 | TSHR (0.58) | MAPK1OPRK1TSHRABCG2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220040318-A1 | PRIMARY AMINE COMPOUND OR SECONDARY AMINE COMPOUND-ACIDIC POLYSACCHARIDE CONJUGATE AND PRODUCTION METHOD THEREFOR | SEIKAGAKU CORPORATION (JP) | 2022-02-10 | — | — | US | disclosed |
| WO-2020067507-A1 | PRIMARY AMINE COMPOUND- OR SECONDARY AMINE COMPOUND-ACIDIC POLYSACCHARIDE CONJUGATE, AND METHOD FOR PRODUCING SAME | 生化学工業株式会社 | 2020-04-02 | — | — | WO | disclosed |
| WO-2020067507-A1 | PRIMARY AMINE COMPOUND- OR SECONDARY AMINE COMPOUND-ACIDIC POLYSACCHARIDE CONJUGATE, AND METHOD FOR PRODUCING SAME | 生化学工業株式会社 | 2020-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220040318-A1 | PRIMARY AMINE COMPOUND OR SECONDARY AMINE COMPOUND-ACIDIC POLYSACCHARIDE CONJUGATE AND PRODUCTION METHOD THEREFOR | ALG1, NGLY1, SAT1 | MAPK1 708/4885OPRK1 3980/4885TSHR 1349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.